WHILE USE OF HOME DIALYSIS MODALITIES REMAINS LOW, INCREASED USE IS EXPECTED IN LIGHT OF THE UPCOMING DIALYSIS BUNDLED PAYMENT SYSTEM
BIOTRENDS RESEARCH GROUP AND THE NATIONAL KIDNEY FOUNDATION TEAM UP TO CAPTURE THE VOICES OF PATIENTS WITH KIDNEY DISEASE
AS THE DIALYSIS BUNDLED PAYMENT PLAN DRAWS NEAR, MEDICAL DIRECTORS AND RENAL ADMINISTRATORS BECOME MORE CONCERNED ABOUT NEGATIVE PATIENT OUTCOMES IN ESRD
RHEUMATOLOGISTS ARE EAGER TO USE ROCHE-GENENTECH’S ACTEMRA ACCORDING TO NEW STUDY BY BIOTRENDS
RHEUMATOLOGISTS HAVE PLENTY OF CHOICE AMONG BIOLOGIC AGENTS FOR RA – WHERE WILL ACTEMRA FIND ITS NICHE?
Read more...
Page 5 of 17
